News | August 26, 2021
Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra
Domestic business was up 41.9% YoY and 27.7% QoQ
Domestic business was up 41.9% YoY and 27.7% QoQ
The company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Through the Sehat Sathi App business can access unsecured business loans at low interest
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
The company reports revenue growth of 26% and PAT growth of 21% YoY
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Subscribe To Our Newsletter & Stay Updated
